Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real‐World Clinical Practice
J Clin Hypertens (Greenwich). 2010;12:396–406. ©2010 Wiley Periodicals, Inc. Hypertension and dyslipidemia are highly co‐prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors. A retrospective cohort study was conducted between January 2004 and April 2008 to compare estima...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2010-06, Vol.12 (6), p.396-406 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 406 |
|---|---|
| container_issue | 6 |
| container_start_page | 396 |
| container_title | The journal of clinical hypertension (Greenwich, Conn.) |
| container_volume | 12 |
| creator | Neutel, Joel M. Eaddy, Michael Lunacsek, Orsolya E. Roberts, Craig Chen, Linda Kean, Allison J. Jackson, James H. |
| description | J Clin Hypertens (Greenwich). 2010;12:396–406. ©2010 Wiley Periodicals, Inc.
Hypertension and dyslipidemia are highly co‐prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors. A retrospective cohort study was conducted between January 2004 and April 2008 to compare estimated 10‐year CHD risk reduction and dual blood pressure and low‐density lipoprotein cholesterol goal attainment (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III]) in patients with a first prescription for amlodipine monotherapy, co‐prescribed amlodipine + statin, or single‐pill amlodipine/atorvastatin. In total, 2739 patients were prescribed amlodipine monotherapy, 653 were co‐prescribed amlodipine + statin, and 227 were prescribed single‐pill amlodipine/atorvastatin. Baseline CHD risk was similar in all 3 cohorts (11.0%–12.5%). Relative CHD risk reduction was greater in those prescribed single‐pill amlodipine/atorvastatin (24.5%) compared with amlodipine monotherapy (14.4%, P |
| doi_str_mv | 10.1111/j.1751-7176.2010.00290.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8673176</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733569385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5040-3c42eed5d8511d05034fbc1310f952012c344bc6167be94443c02a550f2056663</originalsourceid><addsrcrecordid>eNqNUkuOEzEQbSEQ84ErIO9YJWO37f5ICGnoYSagkYiiQbO0HHc1cXDawXbDZMcRuAe34iRUkyGCFXjjUtWrV-Xnl2WE0SnDc7aeslKyScnKYppTzFKa13R69yA7PhQeYixzMSkwc5SdxLimVHJe08fZUU5lzWgljrPv8wCtNQla0vjgex12ZAY6JHJhI-gIZGHjR7KAdjDJ-p7oviUXg3bklfO-Jdge4xDgrFl5BzFB8I5ceayfp6Rtv4E-EduTuU4Ww0hubVqR2W4LIUEfR8abAHqcj6gFaPfj67dbHxzu42xvDTLNg8bZBp5kjzrtIjy9v0-z95evb5rZ5Prd1Zvm_HpiJBV0wo3IAVrZVpKxlkrKRbc0jDPa1RLVyg0XYmkKVpRLqIUQ3NBcS0k7lKUoCn6avdzzboflBlqDewft1DbYDcqjvLbq70pvV-qD_6yqouSoPBI8vycI_tOAqqiNjQac0z34IapSFEyWlaz_jeRcFjWvJCKrPdIEH2OA7rAPo2o0hVqr8e_V-PdqNIX6ZQp1h63P_nzPofG3CxDwYg_4Yh3s_ptYvW1mGPCfDNnI6w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733569385</pqid></control><display><type>article</type><title>Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real‐World Clinical Practice</title><source>MEDLINE</source><source>Wiley Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>PubMed Central</source><creator>Neutel, Joel M. ; Eaddy, Michael ; Lunacsek, Orsolya E. ; Roberts, Craig ; Chen, Linda ; Kean, Allison J. ; Jackson, James H.</creator><creatorcontrib>Neutel, Joel M. ; Eaddy, Michael ; Lunacsek, Orsolya E. ; Roberts, Craig ; Chen, Linda ; Kean, Allison J. ; Jackson, James H.</creatorcontrib><description>J Clin Hypertens (Greenwich). 2010;12:396–406. ©2010 Wiley Periodicals, Inc.
Hypertension and dyslipidemia are highly co‐prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors. A retrospective cohort study was conducted between January 2004 and April 2008 to compare estimated 10‐year CHD risk reduction and dual blood pressure and low‐density lipoprotein cholesterol goal attainment (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III]) in patients with a first prescription for amlodipine monotherapy, co‐prescribed amlodipine + statin, or single‐pill amlodipine/atorvastatin. In total, 2739 patients were prescribed amlodipine monotherapy, 653 were co‐prescribed amlodipine + statin, and 227 were prescribed single‐pill amlodipine/atorvastatin. Baseline CHD risk was similar in all 3 cohorts (11.0%–12.5%). Relative CHD risk reduction was greater in those prescribed single‐pill amlodipine/atorvastatin (24.5%) compared with amlodipine monotherapy (14.4%, P<.01), and co‐prescribed amlodipine + statin (18.4%, P=.01). The findings were driven by greater dual goal attainment for patients prescribed single‐pill amlodipine/atorvastatin (50.2%) compared with amlodipine monotherapy (31.7%, P<.05) and co‐prescribed amlodipine + statin (37.5%, P<.05).</description><identifier>ISSN: 1524-6175</identifier><identifier>EISSN: 1751-7176</identifier><identifier>DOI: 10.1111/j.1751-7176.2010.00290.x</identifier><identifier>PMID: 20591084</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Amlodipine - therapeutic use ; Anticholesteremic Agents - therapeutic use ; Antihypertensive Agents - therapeutic use ; Atorvastatin ; Blood Pressure ; Calcium Channel Blockers - therapeutic use ; Cholesterol, LDL ; Cohort Studies ; Coronary Artery Disease - prevention & control ; Databases, Factual ; Drug Therapy, Combination ; Female ; Health Records, Personal ; Heptanoic Acids - therapeutic use ; Humans ; Hyperlipidemias - drug therapy ; Hypertension - drug therapy ; Male ; Middle Aged ; Original Papers ; Prognosis ; Pyrroles - therapeutic use ; Retrospective Studies ; Risk ; Risk Factors ; Risk Reduction Behavior</subject><ispartof>The journal of clinical hypertension (Greenwich, Conn.), 2010-06, Vol.12 (6), p.396-406</ispartof><rights>2010 Wiley Periodicals, Inc.</rights><rights>Copyright 2010 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5040-3c42eed5d8511d05034fbc1310f952012c344bc6167be94443c02a550f2056663</citedby><cites>FETCH-LOGICAL-c5040-3c42eed5d8511d05034fbc1310f952012c344bc6167be94443c02a550f2056663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673176/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673176/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20591084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neutel, Joel M.</creatorcontrib><creatorcontrib>Eaddy, Michael</creatorcontrib><creatorcontrib>Lunacsek, Orsolya E.</creatorcontrib><creatorcontrib>Roberts, Craig</creatorcontrib><creatorcontrib>Chen, Linda</creatorcontrib><creatorcontrib>Kean, Allison J.</creatorcontrib><creatorcontrib>Jackson, James H.</creatorcontrib><title>Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real‐World Clinical Practice</title><title>The journal of clinical hypertension (Greenwich, Conn.)</title><addtitle>J Clin Hypertens (Greenwich)</addtitle><description>J Clin Hypertens (Greenwich). 2010;12:396–406. ©2010 Wiley Periodicals, Inc.
Hypertension and dyslipidemia are highly co‐prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors. A retrospective cohort study was conducted between January 2004 and April 2008 to compare estimated 10‐year CHD risk reduction and dual blood pressure and low‐density lipoprotein cholesterol goal attainment (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III]) in patients with a first prescription for amlodipine monotherapy, co‐prescribed amlodipine + statin, or single‐pill amlodipine/atorvastatin. In total, 2739 patients were prescribed amlodipine monotherapy, 653 were co‐prescribed amlodipine + statin, and 227 were prescribed single‐pill amlodipine/atorvastatin. Baseline CHD risk was similar in all 3 cohorts (11.0%–12.5%). Relative CHD risk reduction was greater in those prescribed single‐pill amlodipine/atorvastatin (24.5%) compared with amlodipine monotherapy (14.4%, P<.01), and co‐prescribed amlodipine + statin (18.4%, P=.01). The findings were driven by greater dual goal attainment for patients prescribed single‐pill amlodipine/atorvastatin (50.2%) compared with amlodipine monotherapy (31.7%, P<.05) and co‐prescribed amlodipine + statin (37.5%, P<.05).</description><subject>Amlodipine - therapeutic use</subject><subject>Anticholesteremic Agents - therapeutic use</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Atorvastatin</subject><subject>Blood Pressure</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cholesterol, LDL</subject><subject>Cohort Studies</subject><subject>Coronary Artery Disease - prevention & control</subject><subject>Databases, Factual</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Health Records, Personal</subject><subject>Heptanoic Acids - therapeutic use</subject><subject>Humans</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Hypertension - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Papers</subject><subject>Prognosis</subject><subject>Pyrroles - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>Risk Reduction Behavior</subject><issn>1524-6175</issn><issn>1751-7176</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUkuOEzEQbSEQ84ErIO9YJWO37f5ICGnoYSagkYiiQbO0HHc1cXDawXbDZMcRuAe34iRUkyGCFXjjUtWrV-Xnl2WE0SnDc7aeslKyScnKYppTzFKa13R69yA7PhQeYixzMSkwc5SdxLimVHJe08fZUU5lzWgljrPv8wCtNQla0vjgex12ZAY6JHJhI-gIZGHjR7KAdjDJ-p7oviUXg3bklfO-Jdge4xDgrFl5BzFB8I5ceayfp6Rtv4E-EduTuU4Ww0hubVqR2W4LIUEfR8abAHqcj6gFaPfj67dbHxzu42xvDTLNg8bZBp5kjzrtIjy9v0-z95evb5rZ5Prd1Zvm_HpiJBV0wo3IAVrZVpKxlkrKRbc0jDPa1RLVyg0XYmkKVpRLqIUQ3NBcS0k7lKUoCn6avdzzboflBlqDewft1DbYDcqjvLbq70pvV-qD_6yqouSoPBI8vycI_tOAqqiNjQac0z34IapSFEyWlaz_jeRcFjWvJCKrPdIEH2OA7rAPo2o0hVqr8e_V-PdqNIX6ZQp1h63P_nzPofG3CxDwYg_4Yh3s_ptYvW1mGPCfDNnI6w</recordid><startdate>201006</startdate><enddate>201006</enddate><creator>Neutel, Joel M.</creator><creator>Eaddy, Michael</creator><creator>Lunacsek, Orsolya E.</creator><creator>Roberts, Craig</creator><creator>Chen, Linda</creator><creator>Kean, Allison J.</creator><creator>Jackson, James H.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>201006</creationdate><title>Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real‐World Clinical Practice</title><author>Neutel, Joel M. ; Eaddy, Michael ; Lunacsek, Orsolya E. ; Roberts, Craig ; Chen, Linda ; Kean, Allison J. ; Jackson, James H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5040-3c42eed5d8511d05034fbc1310f952012c344bc6167be94443c02a550f2056663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Amlodipine - therapeutic use</topic><topic>Anticholesteremic Agents - therapeutic use</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Atorvastatin</topic><topic>Blood Pressure</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cholesterol, LDL</topic><topic>Cohort Studies</topic><topic>Coronary Artery Disease - prevention & control</topic><topic>Databases, Factual</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Health Records, Personal</topic><topic>Heptanoic Acids - therapeutic use</topic><topic>Humans</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Hypertension - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Papers</topic><topic>Prognosis</topic><topic>Pyrroles - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>Risk Reduction Behavior</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neutel, Joel M.</creatorcontrib><creatorcontrib>Eaddy, Michael</creatorcontrib><creatorcontrib>Lunacsek, Orsolya E.</creatorcontrib><creatorcontrib>Roberts, Craig</creatorcontrib><creatorcontrib>Chen, Linda</creatorcontrib><creatorcontrib>Kean, Allison J.</creatorcontrib><creatorcontrib>Jackson, James H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neutel, Joel M.</au><au>Eaddy, Michael</au><au>Lunacsek, Orsolya E.</au><au>Roberts, Craig</au><au>Chen, Linda</au><au>Kean, Allison J.</au><au>Jackson, James H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real‐World Clinical Practice</atitle><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle><addtitle>J Clin Hypertens (Greenwich)</addtitle><date>2010-06</date><risdate>2010</risdate><volume>12</volume><issue>6</issue><spage>396</spage><epage>406</epage><pages>396-406</pages><issn>1524-6175</issn><eissn>1751-7176</eissn><abstract>J Clin Hypertens (Greenwich). 2010;12:396–406. ©2010 Wiley Periodicals, Inc.
Hypertension and dyslipidemia are highly co‐prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors. A retrospective cohort study was conducted between January 2004 and April 2008 to compare estimated 10‐year CHD risk reduction and dual blood pressure and low‐density lipoprotein cholesterol goal attainment (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [Adult Treatment Panel III]) in patients with a first prescription for amlodipine monotherapy, co‐prescribed amlodipine + statin, or single‐pill amlodipine/atorvastatin. In total, 2739 patients were prescribed amlodipine monotherapy, 653 were co‐prescribed amlodipine + statin, and 227 were prescribed single‐pill amlodipine/atorvastatin. Baseline CHD risk was similar in all 3 cohorts (11.0%–12.5%). Relative CHD risk reduction was greater in those prescribed single‐pill amlodipine/atorvastatin (24.5%) compared with amlodipine monotherapy (14.4%, P<.01), and co‐prescribed amlodipine + statin (18.4%, P=.01). The findings were driven by greater dual goal attainment for patients prescribed single‐pill amlodipine/atorvastatin (50.2%) compared with amlodipine monotherapy (31.7%, P<.05) and co‐prescribed amlodipine + statin (37.5%, P<.05).</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20591084</pmid><doi>10.1111/j.1751-7176.2010.00290.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1524-6175 |
| ispartof | The journal of clinical hypertension (Greenwich, Conn.), 2010-06, Vol.12 (6), p.396-406 |
| issn | 1524-6175 1751-7176 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8673176 |
| source | MEDLINE; Wiley Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; PubMed Central |
| subjects | Amlodipine - therapeutic use Anticholesteremic Agents - therapeutic use Antihypertensive Agents - therapeutic use Atorvastatin Blood Pressure Calcium Channel Blockers - therapeutic use Cholesterol, LDL Cohort Studies Coronary Artery Disease - prevention & control Databases, Factual Drug Therapy, Combination Female Health Records, Personal Heptanoic Acids - therapeutic use Humans Hyperlipidemias - drug therapy Hypertension - drug therapy Male Middle Aged Original Papers Prognosis Pyrroles - therapeutic use Retrospective Studies Risk Risk Factors Risk Reduction Behavior |
| title | Predicted Coronary Heart Disease Risk Reduction and Dual Blood Pressure/Cholesterol Goal Attainment in Patients With Hypertension Treated in Real‐World Clinical Practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A03%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicted%20Coronary%20Heart%20Disease%20Risk%20Reduction%20and%20Dual%20Blood%20Pressure/Cholesterol%20Goal%20Attainment%20in%20Patients%20With%20Hypertension%20Treated%20in%20Real%E2%80%90World%20Clinical%20Practice&rft.jtitle=The%20journal%20of%20clinical%20hypertension%20(Greenwich,%20Conn.)&rft.au=Neutel,%20Joel%20M.&rft.date=2010-06&rft.volume=12&rft.issue=6&rft.spage=396&rft.epage=406&rft.pages=396-406&rft.issn=1524-6175&rft.eissn=1751-7176&rft_id=info:doi/10.1111/j.1751-7176.2010.00290.x&rft_dat=%3Cproquest_pubme%3E733569385%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733569385&rft_id=info:pmid/20591084&rfr_iscdi=true |